JNJ
JNJ clinical trials: JOHNSON & JOHNSON
Every trial on ClinicalTrials.gov where JOHNSON & JOHNSON is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 3,441
- Trials linked
- 2,385
- As lead sponsor
- 1,056
- As collaborator
- 24
- Primary completions as lead sponsor, next 90 days
JNJ on the catalyst calendar · JNJ registry changes
- Primary completion Jan 2, 2029Sponsor estimatePhase 1NCT06768489A Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple...Janssen Research & Development, LLC · Multiple MyelomaRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 5, 2029Sponsor estimatePhase 1NCT07943078A Study of JNJ-99220732 in Participants With Advanced or Metastatic Solid TumorsJanssen Research & Development, LLC · NeoplasmsNot yet recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 4, 2027Sponsor estimatePhase 3NCT06741969Nipocalimab in Moderate to Severe Sjogren's DiseaseJanssen Research & Development, LLC · Sjogrens SyndromeActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 3, 2023ActualPhase 3NCT04513912A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major...Janssen Research & Development, LLC · Depressive Disorder, MajorCompletedJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 23, 2026Sponsor estimateNo phase registeredNCT07735793A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in KoreaJanssen Korea, Ltd., Korea · Urinary Bladder NeoplasmsRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 14, 2028Sponsor estimatePhase 3NCT07906717A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate CancerJanssen Research & Development, LLC · Prostatic NeoplasmsRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 11, 2037Sponsor estimatePhase 3NCT07903272A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in...Janssen Research & Development, LLC · Multiple MyelomaNot yet recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 29, 2032Sponsor estimateNo phase registeredNCT07890285A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in KoreaJanssen Korea, Ltd., Korea · Pulmonary Arterial HypertensionNot yet recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2029Sponsor estimateNo phase registeredNCT07848737A Real-World Study of Guselkumab Persistence and Effectiveness in Participants With Crohn's Disease or Ulcerative ColitisJanssen-Cilag, S.A. · Colitis, UlcerativeNot yet recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 17, 2029Sponsor estimatePhase 2NCT07832292A Study of JNJ-101556143 in Participants With Metastatic Prostate CancerJanssen Research & Development, LLC · Prostatic NeoplasmsRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2030Sponsor estimateNo phase registeredNCT07822529A Study of Long Term Persistency of Guselkumab in Adult Participants With Inflammatory Bowel DiseaseJanssen Research & Development, LLC · Inflammatory Bowel DiseasesRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 3, 2029Sponsor estimateNo phase registeredNCT07746765A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis in Real World SettingJanssen Sciences Ireland UC · Crohn DiseaseNot yet recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 16, 2029Sponsor estimatePhase 1NCT07746713A Study of JNJ-98768111 in Participants With Advanced Prostate CancerJanssen Research & Development, LLC · Prostatic NeoplasmsRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 11, 2029Sponsor estimatePhase 2NCT07746687A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe AsthmaJanssen Research & Development, LLC · AsthmaRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 30, 2029Sponsor estimateNo phase registeredNCT07746583A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical PracticeJanssen-Cilag Kft. · PsoriasisRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 27, 2028Sponsor estimatePhase 3NCT07716098A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant DepressionJanssen Research & Development, LLC · Depressive Disorder, Treatment-ResistantRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 4, 2030Sponsor estimatePhase 3NCT07665450A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab...Janssen Research & Development, LLC · Multiple MyelomaRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2027Sponsor estimatePhase 4NCT07654751A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA TherapeuticallyJanssen Research & Development, LLC · PsoriasisRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 21, 2027Sponsor estimatePhase 1NCT07615426A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With SchizophreniaJanssen Research & Development, LLC · SchizophreniaRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 10, 2029Sponsor estimateNo phase registeredNCT07606339A Study of Guselkumab in Participants With Crohn's Disease and Ulcerative ColitisJanssen-Cilag Pharma GmbH · Crohn DiseaseRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 30, 2029Sponsor estimateNo phase registeredNCT07602088A Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic...Janssen Research & Development, LLC · Leukemia, Lymphocytic, Chronic, B-CellRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimatePhase 2NCT07589634A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in...Janssen Research & Development, LLC · Multiple MyelomaRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2, 2028Sponsor estimatePhase 2NCT07586202A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCJanssen Research & Development, LLC · Carcinoma, Non-Small-Cell LungRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 15, 2028Sponsor estimateNo phase registeredNCT07582783A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in RomaniaJanssen Research & Development, LLC · PsoriasisRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 11, 2028Sponsor estimatePhase 3NCT07577856A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative ColitisJanssen Research & Development, LLC · Colitis, UlcerativeRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 3,416 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner